J
Jimmy Hwang
Researcher at University of California, San Francisco
Publications - 120
Citations - 5081
Jimmy Hwang is an academic researcher from University of California, San Francisco. The author has contributed to research in topics: Cancer & Medicine. The author has an hindex of 33, co-authored 106 publications receiving 4160 citations. Previous affiliations of Jimmy Hwang include University of California.
Papers
More filters
Journal ArticleDOI
Tumor immune profiling predicts response to anti–PD-1 therapy in human melanoma
Adil Daud,Kimberly Loo,Mariela L. Pauli,Robert Sanchez-Rodriguez,Priscila Munoz Sandoval,Keyon Taravati,Katy K. Tsai,Adi Nosrati,Lorenzo Nardo,Michael Alvarado,Alain Algazi,Miguel Hernandez Pampaloni,Iryna Lobach,Jimmy Hwang,Robert H. Pierce,Iris K. Gratz,Matthew F. Krummel,Michael Rosenblum +17 more
TL;DR: The data suggest that the relative abundance of partially exhausted tumor-infiltrating CD8+ T cells predicts response to anti-PD-1 therapy, which can be used to appropriately select patients with a high likelihood of achieving a clinical response to PD-1 pathway inhibition.
Journal ArticleDOI
Liver Metastasis and Treatment Outcome with Anti-PD-1 Monoclonal Antibody in Patients with Melanoma and NSCLC
Paul C. Tumeh,Matthew D. Hellmann,Omid Hamid,Katy K. Tsai,Kimberly Loo,Matthew A. Gubens,Michael Rosenblum,Christina L. Harview,Janis M. Taube,Nathan Handley,Neharika Khurana,Adi Nosrati,Matthew F. Krummel,Andrew Tucker,Eduardo V. Sosa,Phillip J. Sanchez,Nooriel Banayan,Juan C. Osorio,Dan L. Nguyen-Kim,Jeremy Chang,I. Peter Shintaku,Peter D. Boasberg,Emma Taylor,Pamela N. Munster,Alain Algazi,Bartosz Chmielowski,Reinhard Dummer,Tristan Grogan,David Elashoff,Jimmy Hwang,Simone M. Goldinger,Edward B. Garon,Robert H. Pierce,Adil Daud +33 more
TL;DR: Liver metastatic patients with melanoma or NSCLC that had been treated with pembrolizumab were associated with reduced responses and PFS, and liver metastases wereassociated with reduced marginal CD8+ T-cell infiltration, providing a potential mechanism for this outcome.
Journal ArticleDOI
Phase I Study of Sequential Vaccinations With Fowlpox-CEA(6D)-TRICOM Alone and Sequentially With Vaccinia-CEA(6D)-TRICOM, With and Without Granulocyte-Macrophage Colony-Stimulating Factor, in Patients With Carcinoembryonic Antigen–Expressing Carcinomas
John L. Marshall,James L. Gulley,Philip M. Arlen,Patricia Beetham,Kwong-Yok Tsang,Rebecca Slack,James W. Hodge,Sandra Doren,Douglas W. Grosenbach,Jimmy Hwang,Evelyn Fox,Lauretta Odogwu,Susie Park,Dennis Panicali,Jeffrey Schlom +14 more
TL;DR: It is demonstrated that the CEA-TRICOM vaccines are safe and can generate significant CEA -specific immune responses, and they seem to have clinical benefit in some patients with advanced cancer.
Journal ArticleDOI
Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies.
Alain Algazi,Katy K. Tsai,Alexander N. Shoushtari,Rodrigo Ramella Munhoz,Zeynep Eroglu,Josep M. Piulats,Patrick A. Ott,Douglas B. Johnson,Jimmy Hwang,Adil Daud,Jeffrey A. Sosman,Richard D. Carvajal,Bartosz Chmielowski,Michael A. Postow,Jeffrey S. Weber,Ryan J. Sullivan +15 more
TL;DR: Antibodies inhibiting the programmed death receptor 1 (PD‐1) have demonstrated significant activity in the treatment of advanced cutaneous melanoma and the efficacy and safety in patients with uveal melanoma has not been well characterized.
Journal ArticleDOI
Diffusion-weighted MR imaging derived apparent diffusion coefficient is predictive of clinical outcome in primary central nervous system lymphoma.
TL;DR: Evidence is provided that ADC measurements within contrast-enhancing regions of PCNSL tumors may provide noninvasive insight into clinical outcome, and an inverse correlation between cellular density and ADC measurements was observed.